{"id":"NCT01905943","sponsor":"Hoffmann-La Roche","briefTitle":"A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia","officialTitle":"A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11-04","primaryCompletion":"2016-12-29","completion":"2018-10-08","firstPosted":"2013-07-23","resultsPosted":"2018-10-29","lastUpdate":"2019-10-28"},"enrollment":979,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Lymphocytic Leukemia"],"interventions":[{"type":"DRUG","name":"Bendamustine","otherNames":[]},{"type":"DRUG","name":"Chlorambucil","otherNames":[]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Fludarabine","otherNames":[]},{"type":"DRUG","name":"Obinutuzumab","otherNames":["Gazyva®, RO5072759"]}],"arms":[{"label":"Obinutuzumab","type":"EXPERIMENTAL"}],"summary":"This multicenter, open-label, single-arm study will evaluate the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in participants with previously untreated or relapsed/refractory chronic lymphocytic leukemia (CLL). This is a Post-Authorization Safety Study. Participants will receive 6 cycles of single-agent obinutuzumab or obinutuzumab in combination with chemotherapy at the investigator's discretion. Each participant will be followed until 30 months after the last participant has been enrolled. Total length of the study is anticipated to be approximately 5 years.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs)","timeFrame":"Baseline up to time of primary completion (3 years)","effectByArm":[{"arm":"Obinutuzumab","deltaMin":950,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":19},"locations":{"siteCount":174,"countries":["Argentina","Belgium","Bosnia and Herzegovina","Brazil","Canada","Egypt","Estonia","Finland","France","Germany","Greece","Ireland","Israel","Italy","Latvia","Lithuania","Mexico","North Macedonia","Poland","Portugal","Romania","Russia","Serbia","Slovakia","Slovenia","South Korea","Spain","Sweden","Switzerland","Thailand","Turkey (Türkiye)"]},"refs":{"pmids":["33605445","31455851","29749403"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":71,"n":127},"commonTop":["Neutropenia","Thrombocytopenia","Pyrexia","Nausea","Anaemia"]}}